Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp. (Laborie), announced that it has transitioned its Urology (UR) and Gastroenterology (GI) business from a distribution arrangement with Endotherapeutics Pty Ltd to a direct selling model in Australia as of July 1, 2023. This change is in line with Laborie’s long-term business strategy to invest in geographies in which the Company has critical share and to streamline the business model for efficiencies.
Endotherapeutics is a privately owned healthcare technologies company that is an established distributor of medical products. In 2000, Endotherapeutics entered into an agreement with Cogentix Medical (subsequently acquired by Laborie in 2018), to distribute specific product lines in the region. Laborie and Endotherapeutics complementary portfolios and alignment of mission made this a natural partnership.
Laborie will now sell its UR and GI products directly to customers in Australia, except for Macroplastique, Plastique, and VOX which will continue to be exclusively distributed by Endotherapeutics. Laborie has also appointed a new Vice President and General Manager of the APAC region, Antony (Tony) Rayment, who will focus on expanding business in the region and lead a newly formed team to provide first line support to customers. Rayment has over 25 years of experience in the Medical Device industry and has held senior roles across Australia, New Zealand and Asia.
“It’s been a pleasure to work with Endotherapeutics,” said Mike Spicer, Chief Commercial Officer at Laborie. “Laborie is grateful and appreciative of the strategic partnership and we look forward to working together to continue to serve customers in the region.”
“Endotherapeutics is proud to have been Laborie’s Australian distributor for the UR and GI range of products,” said Adam Srejber, CEO of Endotherapeutics. “We would like to thank Laborie for the strong business partnership we have had during this time, the impact we have made on patients’ lives, and we look forward to working with Laborie to ensure a smooth transition to a direct sales model.”
Laborie has an established presence in Australia and currently sells its Obstetrics, Gynecology and Neonatal (OB) products directly to customers. This strategic transition aligns with Laborie’s Vision and signals a continued investment in the market with an emphasis on enhancing customer experience, increasing market share and accelerating growth.
About Laborie Medical Technologies
Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health headquartered in Portsmouth, New Hampshire. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity.
Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class Clinical Education & Information program. For more information visit www.laborie.com.
Laborie is owned by Patricia Industries, a part of Investor AB.
Endotherapeutics is a leading Healthcare Technologies distributor serving customers across Australia and New Zealand, headquartered in Sydney, Australia. Endotherapeutics mission is to improve healthcare and achieves this by supplying innovative healthcare solutions with the highest levels of service and support.
To find out more visit www.endotx.com.au